Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation

Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis. It is marked by extraordinary resistance to conventional therapies including chemotherapy and radiation, as well as to essentially all targeted therapies evaluated so far. More than 90% of PDAC c...

Full description

Bibliographic Details
Main Authors: Laura K. Godfrey, Jan Forster, Sven-Thorsten Liffers, Christopher Schröder, Johannes Köster, Leonie Henschel, Kerstin U. Ludwig, David Lähnemann, Marija Trajkovic-Arsic, Diana Behrens, Aldo Scarpa, Rita T. Lawlor, Kathrin E. Witzke, Barbara Sitek, Steven A. Johnsen, Sven Rahmann, Bernhard Horsthemke, Michael Zeschnigk, Jens T. Siveke
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Clinical Epigenetics
Subjects:
Cancer
Therapy resistance
Epigenetic plasticity
DNA methylation
WGBS
Clonal expansion
Online Access:https://doi.org/10.1186/s13148-024-01623-z

Internet

https://doi.org/10.1186/s13148-024-01623-z

Similar Items